Investigating Public Enthusiasm for Mammography Screening in Denmark

Status Completed

Clinical Trial Summary

Based on an American study by Scherer et al., it is hypothesized that some women will make irrational choices regarding their participation in mammography screening. Therefore, the aim is to estimate the prevalence of Danish women having an irrational preference for mammography screening even when it confers no benefits, but only harms.

Clinical Trial Description

The prevalence of women making an irrational decision will be compared to the participation rate in the Danish screening program. The study population will consist of a random sample of women aged 44-49. Similar to the American study, two types of information will be compared (detailed vs. non-detailed information about the harms of screening). Participants will be randomised to one of two information groups. Based on the American study, it is assumed that the willingness to participate in the hypothetical screening program will be 40 percent. To achieve the desired precision in this study, a standard error of 2.5 percent is required corresponding to a confidence interval spanning approximately 35-45 percent. This will require 384 women in each group, corresponding to a total study population of 768. The survey will be sent electronically (using "e-Boks") with a link to access the online survey trial. The survey will consist of screening and cancer related questions as well as questions on age, education, and health literacy. Five questions on appraisal of health information from the Health Literacy Questionnaire will also be included. After the data collection, data will be linked to data on income, residence, civil status, education, breast cancer diagnosis, and information on whether a participant is immigrant, descendent or of Danish origin. The original plan for the main analysis was to compare the two groups of women randomized to different information groups (detailed vs. non-detailed information about the harms of screening). However, due to lower participation rate and therefore smaller sample size than expected, information group was disregarded in the main analysis. The two groups will still be compared in a secondary analysis. This decision was made before getting access to data from the questionnaire. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04509063
Study type	Interventional
Source	University of Aarhus
Contact
Status	Completed
Phase	N/A
Start date	November 6, 2020
Completion date	January 4, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03980626` - Study on Physical Activity's Relationship With Cancer and Cognition	N/A
Completed	`NCT04329819` - Satisfaction and QUality of Life After Breast REconstruction
Recruiting	`NCT03323346` - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	Phase 2
Active, not recruiting	`NCT03900884` - Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer	Phase 1
Completed	`NCT05042999` - The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures	N/A
Not yet recruiting	`NCT03662633` - Diagnosis Value of SEMA4C in Breast Cancer
Recruiting	`NCT05075512` - The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer	Phase 2
Recruiting	`NCT04456855` - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Not yet recruiting	`NCT03629509` - BEFORE Decision Aid Implementation Study	N/A
Completed	`NCT04811378` - HaemoCerTM Application in Breast Cancer Surgery	N/A
Completed	`NCT03198442` - Breast PET Feasibility	N/A
Not yet recruiting	`NCT05577442` - Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer	Phase 2
Enrolling by invitation	`NCT04047823` - Temperature and Injury in Radiotherapy Radiation Skin Injury
Recruiting	`NCT05452213` - Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients	Phase 4
Recruiting	`NCT05027321` - Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies	N/A
Active, not recruiting	`NCT04812652` - Digitally Distributed Yoga for Women Treated for Breast Cancer	N/A
Active, not recruiting	`NCT03425838` - Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	Phase 3
Completed	`NCT05473026` - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors	N/A
Recruiting	`NCT05711030` - Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery	N/A
Suspended	`NCT03271853` - Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.